Far more than 99.9% of the women given GARDASIL would not get cervical cancer with or without it. So if there is
ANY risk associated with this vaccine, the risks could far outweigh the benefits.
For example, the alum adjuvant in this vaccine was recently shown to cause to neural death in mice.
News rticle:
http://www.straight.com/article/vaccines-show-sinister-sidePeer reviewed medical journal paper:
http://tinyurl.com/3xhtdz In addition,
http://www.nvic.org/Diseases/HPV/HPVrpt.htmA 16-year-old Illinois girl was vaccinated July 7th and 13 days later developed symptoms eventually diagnosed as Guillian-Barre Syndrome. A 14-year-old girl in the District of Columbia was vaccinated on July 11th and complained of severe pain immediately following the injection, fell off the examining table and experienced a 10 to 15 second fainting spell ending up in the emergency room with a headache and speech problems. Note that when Merck did the tests on GARDASIL's safety, they used a shot of alum (aluminum salt) as the "control placebo."
http://www.ahrp.org/cms/content/view/263/28/According to the Merck product manufacturer insert, there was 1 case of juvenile arthritis, 2 cases of rheumatoid arthritis, 5 cases of arthritis, and 1 case of reactive arthritis in 11,813 Gardasil recipients plus 1 case of lupus and 2 cases of arthritis out of 9,701 participants primarily receiving an aluminum containing placebo. Clinical trial investigators dismissed most of the 102 Gardasil and placebo associated serious adverse events, including 17 deaths, that occurred in the clinical trials as unrelated.If just one of these serious cases was due to adverse effects from the vaccination, the whole "benefit" profile of GARDASIL goes out the window. Less than 2.5 out of every 100,000 US women dies from cervical cancer annually, and HPV screening has reduced that number by about 75% over the last four decades. At best, only 70% of these cases could be helped by GARDASIL. Now compare this to 1 out of 22,000 (the total number of subjects in the GARDASIL tests including "placebo" subjects) getting a major vaccine-related illness over the (at most) four year follow up period of the studies. Now consider that this vaccine was tested on less than 1,200 girls under 16 and the follow up period for this study lasted only 18 months.